Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 148

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 148
---
legal and reputational risks. Failure to comply could lead to regulatory scrutiny, consumer lawsuits, or loss of market confidence, particularly
given past skepticism about resveratrol’s safety and efficacy at high doses.

PHARMACEUTICAL PRODUCT PIPELINE

The Company’s pharmaceutical
product pipeline is built around its proprietary platform product, JOTROL™ an enhanced oral formulation of resveratrol.
Resveratrol, a natural compound is optimized in JOTROL™ to deliver therapeutically effective doses safety, aiming to address
oxidative stress, inflammation and mitochondrial issues linked to neurological conditions. The Company has designated the different indications
with project numbers, JNS101 - JNS115. The same JOTROL™ product is planned to be used in all indications although the number
of capsules might vary and be indication specific.

| 83 |

The pipeline chart above shows
the indications that we presently are prioritizing. However, JNS101 is an additional indication that we believe will be of interest to
perform a clinical trial in at a later stage.

The product pipeline represented
above assumes drawing upon previous preclinical and clinical data conducted by third parties. This data is available either via public
domain or under agreements with our key partners. The Company has not discussed with the FDA its ability to rely on and reference data
from previous third-party trials, such as the Phase II trial in MCI/early Alzheimer’s disease, conducted by Georgetown University.

Our top priorities are advancing
our clinical studies for JNS115 for Parkinson’s Disease. We have started the work with the JNS115 Phase IIa trial and estimate that
first dosing of patients will occur in Q4 of 2025.

We have not set any timeline
for starting clinical trials for rare diseases. We may work with other strategic partners on these clinical trials.

JNS115 Parkinson’s Disease

We will be utilizing JOTROL™
in our application for investigating a treatment for Parkinson’s Disease (PD).

People are usually more familiar
with the motor symptoms of Parkinson’s disease (PD), which are noticeable and used by doctors for diagnosis. The three cardinal
motor symptoms are stiffness (rigidity), slowness (bradykinesia), and resting tremors. Stiffness involves muscle rigidity detected during
examination, while slowness refers to decreased spontaneous and voluntary movement, such as slower walking or reduced facial expression.
Resting tremor is an involuntary shaking that occurs when a limb is relaxed and disappears during movement.